Table A8.

Multivariate Analysis Including Post-Treatment SUV_peak (institutional read) as a Variable, After Excluding Patients With Distant Metastatic Disease Diagnosed on the Post-Treatment PET and Confirmed by Follow-Up (n = 28)

Parameter	Hazard Ratio	95% CI	P
Age (years): continuous	1.013	0.987 to 1.039	.337
Sex: female v male	1.001	0.632 to 1.585	.997
Performance status: ambulatory, capable of light work v fully active	1.147	0.749 to 1.757	.528
Clinical stage
IIIA v IIB	0.744	0.277 to 2.002	.559
IIIB v IIB	0.848	0.308 to 2.336	.750
Radiotherapy dose (Gy): continuous	0.976	0.930 to 1.024	.320
Chemotherapy regimen
Cisplatin + etoposide v carboplatin + paclitaxel	1.131	0.592 to 2.160	.710
Other v carboplatin + paclitaxel	1.325	0.821 to 2.138	.250
Post-treatment SUVpeak: continuous	1.061	0.974 to 1.156	.176

Abbreviations: PET, positron emission tomography; SUV_peak, peak standardized uptake value.